ReviewActa neurologica Belgica2023
Minimal symptom expression achievement over time in generalized myasthenia gravis.
Review in Acta neurologica Belgica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Real-World Clinical Outcomes and Corticosteroid Tapering in Telitacicept-Based Therapy for Ocular Myasthenia Gravis: An Exploratory Analysis by Prior Treatment History.Brain and behavior · 2026Article
- Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China.Neurology and therapy · 2026Article
- Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal.European journal of neurology · 2026Review
- Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study.European journal of neurology · 2026Article
- Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.Frontiers in immunology · 2026Article
- Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.Therapeutic advances in neurological disorders · 2026Article
- Individualized Dosing of Efgartigimod in Patients With Generalized Myasthenia Gravis: Clinical Experience at a Single Center.Muscle & nerve · 2025Article
- Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neonatal intensive care unit.BMC neurology · 2025Article
- Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect.Frontiers in immunology · 2025Article
- Article
- Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation.Frontiers in neurology · 2024Article
- Optimal time for the addition of non-corticosteroid immunosuppressants in myasthenia gravis: a single-center retrospective study in China.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectivesMinimal symptom expression (MSE), defined as myasthenia gravis (MG) activities of daily living profile (MGADL) score 0 or 1, has been recently used as an indicator of treatment goal in MG. However, no study has determined when MSE is achieved. The current study aimed to investigate the timing and incidence of MSE achievement in generalized MG patients.
methodsEighty-five patients with acetylcholine receptor antibody-positive generalized MG were included. They were followed-up maximum 3 years after starting immunotherapy, and we reviewed the MGADL score, prednisolone dose, and achievement of MSE and minimal manifestations (MM) or better status.
resultsMSE was achieved in 37.6, 45.2, 55.8, 60.3, and 57.1% of the patients at 3, 6, 12, 24, and 36 months after treatment, respectively. Most patients who achieved MSE showed MM or better status at any phase. In addition, more than 2 years after the starting treatment, about 80% of patients who achieved MSE showed MM or better status with an oral prednisolone dose of 5 mg/day or less (MM-5 mg). Noteworthy, during the early stage of treatment, the proportion of patients who achieved MSE was higher than that who achieved MM-5 mg.
conclusionFrom the early phases of immunotherapy, MSE is a good marker of therapeutic goal in patients with generalized MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.